Sugi Predict

Sugi Predict / Compounds / SCHEMBL509416

SCHEMBL509416

SCHEMBL509416

C=C1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ KDM1A O60341 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CTSK P43235 2/20 0.47
▸ GAA P10253 2/20 0.45
▸ DRD2 P14416 2/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ KCNA3 P22001 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CKS1B P61024 1/20 0.40
▸ SKP1 P63208 1/20 0.40
▸ SKP2 Q13309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL17140922 0.98 CTSK (0.49) BTKKDM1AMAOBCTSKGAA
SCHEMBL24424522 0.94 BTK (0.52) BTKKDM1AMAOBCTSKGAA
SCHEMBL27063727 0.94 BTK (0.52) BTKKDM1AMAOBCTSKGAA
SCHEMBL27419729 0.94 BTK (0.52) BTKKDM1AMAOBCTSKGAA
SCHEMBL26135662 0.84 BTK (0.51) BTKKDM1AMAOBCTSKGAA
SCHEMBL117269 0.84 BTK (0.51) BTKKDM1AMAOBCTSKGAA
SCHEMBL571098 0.84 BTK (0.50) BTKKDM1AMAOBCTSKGAA
SCHEMBL10343938 0.83 BTK (0.61) BTKKDM1AMAOBCTSKGAA
SCHEMBL3702157 0.83 BTK (0.61) BTKKDM1AMAOBCTSKGAA
SCHEMBL3702152 0.83 BTK (0.61) BTKKDM1AMAOBCTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115835909-B Cannabinoid receptor type 2 (CB 2) modulators and uses thereof 泰昂治疗公司 2026-05-15 — — CN disclosed
US-20240252504-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS INC (US) 2024-08-01 — — US disclosed
US-12030897-B2 Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof MEDSHINE DISCOVERY INC. (CN) 2024-07-09 — — US disclosed
US-12030897-B2 Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof MEDSHINE DISCOVERY INC. (CN) 2024-07-09 — — US disclosed
US-11957689-B2 Cannabinoid receptor type 2 (CB2) modulators and uses thereof TEON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
WO-2023178181-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-09-21 — — WO disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 — — EP disclosed
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC 2023-05-11 — — US disclosed
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC 2023-05-11 — — US disclosed
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC 2023-05-11 — — US disclosed
WO-2010130034-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — WO disclosed
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-11-18 — — US disclosed
US-7825147-B2 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2010-11-02 — — US disclosed
US-20100056756-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2010-03-04 — — US disclosed
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2010-02-11 — — US disclosed
EP-2137143-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES Nabriva Therapeutics AG (AT) 2009-12-30 — — EP disclosed
WO-2008113089-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES NABRIVA THERAPEUTICS AG (AT) 2008-09-25 — — WO disclosed
EP-1663999-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES, LTD. (IN) 2006-06-07 — — EP disclosed
US-20050075383-A1 Inhibitors of phophodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 — — US disclosed
WO-2005021515-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF CNR2, CNR1, GPR18 BTK 1762/4885KDM1A 3499/4885MAOB 1369/4885
US-20100292227-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, RTF1 BTK 2768/4885KDM1A 1193/4885MAOB 2197/4885
US-20100056756-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS PRSS1, PRSS8, PRSS2 BTK 4846/4885KDM1A 3523/4885MAOB 2966/4885
US-20100035987-A1 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES FABP2, FABP6, ALPI BTK 3006/4885KDM1A 4806/4885MAOB 2002/4885
US-12030897-B2 Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof ERBB2, EGFR, ERBB3 BTK 156/4885KDM1A 2018/4885MAOB 1623/4885
US-20240252504-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF CNR2, CNR1, GPR18 BTK 1762/4885KDM1A 3499/4885MAOB 1369/4885
US-11957689-B2 Cannabinoid receptor type 2 (CB2) modulators and uses thereof CNR2, CNR1, GPR18 BTK 1762/4885KDM1A 3499/4885MAOB 1369/4885
US-20050075383-A1 Inhibitors of phophodiesterase type-IV PDE7A, PDE4A, PDE4B BTK 803/4885KDM1A 3228/4885MAOB 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.